Search

Your search keyword '"Frascaroli G"' showing total 7 results
Start Over Author "Frascaroli G" Publisher elsevier bv
7 results on '"Frascaroli G"'

3. Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Outcome, Treatment Strategies and Analysis of Risk Factors

Author

Loforte, A., primary, Pilato, E., additional, Martin Suarez, S., additional, Jafrancesco, G., additional, Castrovinci, S., additional, Cefarelli, M., additional, Potena, L., additional, Masetti, M., additional, Magnani, G., additional, Grigioni, F., additional, Frascaroli, G., additional, and Marinelli, G., additional

Published
2015
Full Text
View/download PDF

4. Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Treatment Strategies and Analysis of Risk Factors

Author

Loforte, A., primary, Marinelli, G., additional, Musumeci, F., additional, Pilato, E., additional, Martin Suarez, S., additional, Montalto, A., additional, Folesani, G., additional, Castrovinci, S., additional, Iafrancesco, G., additional, Lilla Della Monica, P., additional, Grigioni, F., additional, Potena, L., additional, Frascaroli, G., additional, and Arpesella, G., additional

Published
2014
Full Text
View/download PDF

7. The novel anti-rheumatic compound Rabeximod impairs differentiation and function of human pro-inflammatory dendritic cells and macrophages

Author

Stefania Varani, Cecilia Söderberg-Nauclér, Pablo Giusti, Charlotte Tammik, Sara Gredmark-Russ, Giada Frascaroli, Giusti P., Frascaroli G., Tammik C., Gredmark-Russ S., Soderberg-Naucler C., and Varani S.

Subjects
Isoantigens, Indoles, Myeloid, Immunology, Inflammation, Lymphocyte Activation, Peripheral blood mononuclear cell, Monocytes, Arthritis, Rheumatoid, Phagocytosis, Antigen, Quinoxalines, Humans, Immunology and Allergy, Medicine, Cell Lineage, RHEUMATOID ARTHRITIS, Cells, Cultured, Antigen Presentation, business.industry, Macrophages, Monocyte, Cell Differentiation, Dendritic Cells, Hematology, Colony-stimulating factor, medicine.anatomical_structure, antigen presenting cell, Monocyte differentiation, Pinocytosis, Cytokine secretion, medicine.symptom, business
Abstract

Rabeximod (9-chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b]quinoxaline) is a synthetic compound that is currently being developed for the treatment of rheumatoid arthritis (RA). Here, we investigated the effects of Rabeximod on the functionality of human antigen-presenting cells (APCs) of myeloid origin. Different subsets of professional APCs were generated from human monocytes in vitro and simultaneously treated with different doses of Rabeximod. Although Rabeximod had no effect on the differentiation of monocytes into anti-inflammatory macrophages (AI-Mϕs), this compound impaired monocyte differentiation into monocyte-derived dendritic cells (MDCs) and pro-inflammatory allostimulated macrophages (Allo-Mϕs). MDCs that were treated with Rabeximod resulted in a significant decrease in their ability to pinocytose antigens, while no effect was exerted by the drug on the ability of Allo-Mϕs and AI-Mϕs to phagocytose. Furthermore, we observed a significant reduction in the allostimulatory ability of MDCs and Allo-Mϕs after treatment with Rabeximod, although this compound did not affect the low immunostimulatory capacity of AI-Mϕs. Conversely, the effect of Rabeximod in influencing cytokine secretion by APCs appeared to be limited. In conclusion, Rabeximod impairs differentiation of monocytes into different pro-inflammatory APCs, leading to impaired immunostimulatory abilities of these cells. Our observations shed light on the cellular mode of action and the immunomodulatory effect of Rabeximod.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results